Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

ConclusionsOur results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US.
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research